Reduced gut microbiota diversity in ulcerative colitis patients with latent tuberculosis infection during vedolizumab therapy: insights on prophylactic anti-tuberculosis effects
Authors:
Open Access
- 27 December 2024
- journal article
- research article
- Published by Springer Nature in BMC Microbiology
- Vol. 24 (1) , 1-13
Abstract
The gut microbiota plays a pivotal role in ulcerative colitis (UC) development. This study explores the impact of latent tuberculosis infection (LTBI) on the gut microbiota in UC and assesses changes during vedolizumab treatment, investigating prophylactic anti-tuberculosis therapy. This cohort study included adult patients with UC receiving vedolizumab treatment at Jinhua Hospital, Zhejiang University from April 2021 to December 2022. Patients were divided into LTBI (n = 24) and non-LTBI (n = 21) groups. Patients in the LTBI group were further subdivided into prophylactic (n = 13) and non-prophylactic (n = 11) groups. Clinical and fecal samples were collected pre- and post-vedolizumab treatment for the LTBI groups and pre-treatment for the non-LTBI group. The gut microbiota was analyzed using 16 S rRNA sequencing. Patients in the non-LTBI group exhibited higher diversity indices. Vedolizumab demonstrated efficacy in the LTBI group, with clinical response and remission rates of 83.3% and 75.0%, respectively. The gut microbiota diversity in the LTBI group increased post-vedolizumab treatment, and receiving prophylactic isoniazid showed no significant difference in vedolizumab treatment response compared to not receiving prophylactic isoniazid. Microbiota changes were similar between groups, with an increase in [Ruminococcus] expression after vedolizumab treatment. This cohort study, conducted at a single center, highlights that LTBI can reduce gut microbiota diversity among adult patient with UC. The observed efficacy of vedolizumab treatment in the LTBI group indicates a potential association with microbiota changes. However, mono-isoniazid exhibited limited impact, underscoring the potential of vedolizumab as a promising candidate for prophylactic anti-tuberculosis treatment in the context of UC.Keywords
Funding Information
- Department of Health of Zhejiang Province (2019RC302)
- Science and Technology Plan Project of Jinhua Municipal Central Hospital (JY2020-6-06)
This publication has 43 references indexed in Scilit:
- Ulcerative colitisThe Lancet, 2023
- Gut microbiota associated with pulmonary tuberculosis and dysbiosis caused by anti-tuberculosis drugsJournal of Infection, 2019
- The Short Chain Fatty Acid Butyrate Imprints an Antimicrobial Program in MacrophagesImmunity, 2019
- Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studiesThe Lancet, 2017
- Gut Microbiome Function Predicts Response to Anti-integrin Biologic Therapy in Inflammatory Bowel DiseasesCell Host & Microbe, 2017
- Microbial shifts and signatures of long-term remission in ulcerative colitis after faecal microbiota transplantationThe ISME Journal, 2017
- The global burden of IBD: from 2015 to 2025Nature Reviews Gastroenterology & Hepatology, 2015
- Cytokines in inflammatory bowel diseaseNature Reviews Immunology, 2014
- Predictive functional profiling of microbial communities using 16S rRNA marker gene sequencesNature Biotechnology, 2013
- Reduced Diversity and Imbalance of Fecal Microbiota in Patients with Ulcerative ColitisDigestive Diseases and Sciences, 2012